Avexis (AVXS) was downgraded to hold at Jefferies. The valuation is less attractive, based on a $42 price target, Jefferies said.
Priceline (PCLN) was upgraded to overweight from equal-weight at Barclays. $1,500 price target. Expect long-term structural growth and compelling end-market demand, Barclays said.
Surgical Care (SCAI) was downgraded to neutral from buy at Goldman Sachs. $48 price target. The valuation is less attractive, with shares up 21% over the past six months, Goldman said.